Alkem Laboratories Slips as Q2 Net Profit Drops 12% to Rs 675 Crore Despite Solid Revenue Gains

Alkem Laboratories Limited reported its financial results for the second quarter, delivering double-digit top-line growth that was overshadowed by bottom-line contraction and margin pressures, prompting brokerages and market analysts to revise their earnings estimates.

Consolidated revenue from operations increased by 13.77% year-on-year to Rs 4,551.99 crore compared to Rs 4,000.99 crore in the corresponding period of the previous fiscal year. Sequentially, revenue advanced 21.7% from Rs 3,740.15 crore in the prior quarter. However, consolidated net profit attributable to shareholders declined 11.73% year-on-year to Rs 675.34 crore from Rs 765.06 crore, missing consensus market expectations of Rs 690 crore.

Following the earnings release, shares of Alkem Laboratories slipped over 2.7% toward Rs 5,300 on the National Stock Exchange (NSE) and BSE as market participants adjusted to the profit contraction.

Key Financial Highlights:

• Total income for the quarter reached Rs 4,686.20 crore, rising 14.2% year-on-year from Rs 4,104.68 crore.
• Operating EBITDA grew 11.3% year-on-year to Rs 1,025.20 crore, though EBITDA margins contracted by 50 basis points to 22.5%.
• Gross margins expanded 220 basis points to 67.2% from 65.0% in the prior year, buoyed by a favorable product mix and operational efficiencies in the core pharmaceutical franchise.
• Total tax expense surged to Rs 331.90 crore compared to Rs 116.20 crore a year earlier, following the company's transition to the new corporate tax regime.
• Basic and diluted earnings per share (EPS) stood at Rs 56.48, down from Rs 63.99 in the year-ago quarter.

Segmental Performance and Geographic Footprint

The domestic market remained the core anchor of Alkem's operational profile, contributing roughly 68% of total revenue. Domestic formulations sales climbed 9.5% year-on-year to Rs 3,027.50 crore, supported by a 12.1% expansion in the branded prescription business, while trade generics recorded mid-single-digit gains. The company maintained its standing as India's third-largest player in acute therapies while steadily pushing into chronic therapeutic categories.

International markets showed divergent trajectories:

• US sales recorded modest growth of 2.4% year-on-year to Rs 783.00 crore, reflecting continued generic pricing headwinds and selective portfolio rationalisation across its 170 approved Abbreviated New Drug Applications (ANDAs).
• Non-US international operations surged 58% year-on-year to Rs 671.00 crore, driven by strong commercial momentum in key emerging markets.
• Emerging segments contributed incrementally, with Biotech operations delivering Rs 70.40 crore and MedTech generating Rs 133.10 crore.

Cost Pressures and Strategic Bets

The margin compression witnessed during the quarter was primarily driven by integration costs and pre-operative expenditures linked to the company's diversification drive. Alkem completed the acquisition of Switzerland-based structural heart device maker Occlutech Holding AG in July 2026, marking a significant foray into the higher-margin medical technology segment, while commercial scale-up expenses at its Enzene Biosciences CDMO unit also weighed on near-term profitability.

Management noted that the balance sheet remains conservative, with a net cash position of Rs 4,905.40 crore as of September 30, offering sufficient liquidity to absorb gestation costs in these newer verticals. In a simultaneous regulatory update, Alkem announced that its board approved the appointment of Gopal Kothari as Chief Financial Officer and Key Managerial Personnel, effective December 2, following the resignation of former CFO Nitin Agrawal.

Analyst Reactions and Outlook

Brokerage responses have turned more measured, balancing steady domestic execution against elevated operational expenditures. While gross margin resilience and acute segment leadership provide downside support, analysts note that the timeline for earnings accretion from Occlutech and Enzene will dictate whether the stock can reclaim the upper band of its 52-week trading range. Near-term focus for investors will center on the commercial turnaround in the US generic business and margin stabilization in the upcoming quarters.